JUNE 5, 2006
PERKINELMER INTRODUCES ITS NEW PAX- 6, PRECISION ALIGNED XENON
6-WATT LIGHTSOURCE, FOR CLINICAL DIAGNOSTICS AND LIFE SCIENCE APPLICATIONS
Precision Aligned Arc Positioning Provides OEMs With “Plug and Play”
Field Replacement
Salem, MA — PerkinElmer Optoelectronics, a global technology leader in digital imaging, specialty lighting and optical detection technologies, today announced the availability of its new PAX-6, a Precision Aligned 6-Watt Xenon integrated lightsource for a variety of Clinical Diagnostics, Life Science, and Analytical Instrumentation applications.
These fully integrated lamp modules contain the 6-Watt Xenon flash lamp, trigger circuit and power supply required to produce microsecond pulses of broadband light with exceptional arc stability.
“PerkinElmer designed the PAX-6 specifically in response to OEMs’ needs for precision arc alignment. We believe that this new product introduction delivers exceptional performance and value and offers a real step-change in installation ease and field replacement convenience,” stated David Nislick, Vice President and General Manager, Biomedical Products, PerkinElmer Optoelectronics.
The PAX-6 offers a wide range of flash energy levels, 6-Watt average power, and is available in two arc orientations. The compact module features PerkinElmer’s reliable pulsed Xenon flashlamp technology, delivering high radiant intensity and a long life rating of 1×109 flashes. The PAX-6 is available now and is fully RoHS compliant and CE-marked.
PerkinElmer Optoelectronics is a global technology leader in digital imaging, specialty lighting and optical detection technologies. We provide applications-driven, integrated solutions to leading OEMs in Health Sciences and Industrial Science markets. More information about PerkinElmer Optoelectronics recent announcements is available at http://optoelectronics.perkinelmer.com/content/corporate/news/pressreleases.aspx.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
###
